Synopsys Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synopsys in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Synopsys stock.
View analyst ratings for Synopsys or view top-rated stocks.

11 analysts have issued 12-month target prices for Synopsys' shares. Their SNPS stock forecasts range from $340.00 to $445.00. On average, they expect Synopsys' stock price to reach $377.45 in the next year. This suggests a possible upside of 24.7% from the stock's current price.
View analysts' price targets for Synopsys or view top-rated stocks among Wall Street analysts.

Synopsys' stock was trading at $368.50 at the beginning of 2022. Since then, SNPS stock has decreased by 17.9% and is now trading at $302.71.
View the best growth stocks for 2022 here.

Synopsys is scheduled to release its next quarterly earnings announcement on Wednesday, August 17th 2022.
View our earnings forecast for Synopsys.

Synopsys, Inc. (NASDAQ:SNPS) posted its quarterly earnings results on Wednesday, May, 18th. The semiconductor company reported $1.89 EPS for the quarter, topping the consensus estimate of $1.80 by $0.09. The semiconductor company had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.25 billion. Synopsys had a net margin of 21.19% and a trailing twelve-month return on equity of 18.23%. During the same quarter last year, the company earned $1.24 earnings per share.
View Synopsys' earnings history.

Synopsys announced that its board has authorized a share buyback plan on Friday, December 10th 2021, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 1.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board believes its stock is undervalued.

Synopsys updated its third quarter 2022 earnings guidance on Wednesday, June, 15th. The company provided earnings per share guidance of $2.01-$2.06 for the period, compared to the consensus EPS estimate of $1.61. The company issued revenue guidance of $1.21 billion-$1.24 billion, compared to the consensus revenue estimate of $1.14 billion.

1,170 employees have rated Synopsys CEO Dr. Aart J. de Geus and Dr. Chi-Foon Chan on Glassdoor.com. Dr. Aart J. de Geus and Dr. Chi-Foon Chan has an approval rating of 95% among Synopsys' employees. This puts Dr. Aart J. de Geus and Dr. Chi-Foon Chan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Synopsys include Adobe (ADBE), Salesforce (CRM), Intuit (INTU), Cadence Design Systems (CDNS), Autodesk (ADSK), Workday (WDAY), ANSYS (ANSS), SS&C Technologies (SSNC), Splunk (SPLK), FactSet Research Systems (FDS), Tyler Technologies (TYL), Aspen Technology (AZPN), Citrix Systems (CTXS), Fair Isaac (FICO) and Manhattan Associates (MANH).
View all of SNPS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synopsys investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Square (SQ), Salesforce (CRM), Advanced Micro Devices (AMD), Adobe (ADBE), Tesla (TSLA), Netflix (NFLX) and Micron Technology (MU).

Synopsys trades on the NASDAQ under the ticker symbol "SNPS."

Synopsys' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.33%), BlackRock Inc. (8.84%), State Street Corp (4.12%), JPMorgan Chase & Co. (3.04%), Invesco Ltd. (1.70%) and Massachusetts Financial Services Co. MA (1.33%). Company insiders that own Synopsys stock include Bruce R Chizen, Chi-Foon Chan, Chrysostomos L Nikias, Geus Aart De, Janice Chaffin, John F Runkel Jr, Joseph W Logan, Mercedes Johnson, Roy Vallee, Sassine Ghazi, Steven Walske, Sudhindra Kankanwadi and Trac Pham.
View institutional ownership trends for Synopsys.

SNPS stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments LLC, California Public Employees Retirement System, Nordea Investment Management AB, Twin Tree Management LP, 1832 Asset Management L.P., Mackenzie Financial Corp, Mirae Asset Global Investments Co. Ltd., and Mirae Asset Global Investments Co. Ltd.. Company insiders that have sold Synopsys company stock in the last two years include Chi-Foon Chan, Chrysostomos L Nikias, Geus Aart De, Janice Chaffin, John F Runkel Jr, Joseph W Logan, Mercedes Johnson, Roy Vallee, Sassine Ghazi, Steven Walske, Sudhindra Kankanwadi, and Trac Pham.
View insider buying and selling activity for Synopsys or view top insider-selling stocks.

SNPS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Van ECK Associates Corp, Vanguard Group Inc., Polar Capital Holdings Plc, Invesco Ltd., Wellington Management Group LLP, and Prudential Financial Inc..
View insider buying and selling activity for Synopsys or or view top insider-buying stocks.

Shares of SNPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SNPS stock can currently be purchased for approximately $302.71.

Synopsys (NASDAQ:SNPS) has a market capitalization of $46.31 billion and generates $4.20 billion in revenue each year. The semiconductor company earns $757.52 million in net income (profit) each year or $6.429990 on an earnings per share basis.

Synopsys employs 16,361 workers across the globe.

Synopsys was founded in 1986.

Synopsys' mailing address is 690 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for Synopsys is www.synopsys.com. The semiconductor company can be reached via phone at (650) 584-5000, via email at [email protected], or via fax at 650-965-8637.